Idelalisib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

References

• Hallek M . Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am. J. Hematol.90(5), 446–460 (2015).
   PubMed Web of Science ®Google Scholar
• SEER Stat Fact Sheets: Leukemia. http://seer.cancer.gov/statfacts/html/leuks.html.
   Google Scholar
• American Cancer Society . Cancer Facts & Figures 2015. www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
   Google Scholar
• Gribben JG . How I treat CLL up front. Blood115(2), 187–197 (2010).
   PubMed Web of Science ®Google Scholar
• CLL Trialists’ Collaborative Group . Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J. Natl Cancer Inst.91(10), 861–868 (1999).
   PubMed Web of Science ®Google Scholar
• Hallek M , ChesonBD, CatovskyDet al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood111(12), 5446–5456 (2008).
   PubMed Web of Science ®Google Scholar
• Smith A , HowellD, PatmoreR, JackA, RomanE. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br. J. Cancer105(11), 1684–1692 (2011).
   PubMed Web of Science ®Google Scholar
• Thurmes P , CallT, SlagerSet al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk. Lymphoma49(1), 49–56 (2008).
   PubMed Web of Science ®Google Scholar
• Gribben JG . Chronic lymphocytic leukemia: planning for an aging population. Expert Rev. Anticancer Ther.10(9), 1389–1394 (2010).
   PubMed Web of Science ®Google Scholar
• SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. http://seer.cancer.gov/statfacts/html/nhl.html.
   Google Scholar
• Baumann T , DelgadoJ, SantacruzRet al. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. Haematologica99(10), 1599–1604 (2014).
   PubMed Web of Science ®Google Scholar
• Satram-Hoang S , ReyesC, HoangKQ, MominF, SkettinoS. The unmet need in chronic lymphoctytic leukemia: impact of comorbidity burden on treatment patterns and outcomes in elderly patients. J. Cancer Ther.4, 1321–1329 (2013).
   Google Scholar
• Eichhorst B , GoedeV, HallekM. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk. Lymphoma50(2), 171–178 (2009).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas (version 1.2015). www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
   Google Scholar
• Morabito F , GentileM, SeymourJF, PolliackA. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target. Leuk. Lymphoma56(12), 3250–3256 (2015).
   PubMed Web of Science ®Google Scholar
• Rai KR . Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J. Hematol. Oncol.8(1), 85 (2015).
   PubMedGoogle Scholar
• Barrientos JC . Management of chronic lymphocytic leukemia in the elderly. Cancer Control22(4 Suppl.), 17–23 (2015).
   PubMed Web of Science ®Google Scholar
• Swerdlow SH , CampoE, HarrisNLet al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues . IARC Press, Lyon, France (2008).
   Google Scholar
• Tsimberidou AM , WenS, O’BrienSet al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J. Clin. Oncol.25(29), 4648–4656 (2007).
   PubMed Web of Science ®Google Scholar
• Hallek M , FischerK, Fingerle-RowsonGet al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet376(9747), 1164–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Strati P , WierdaW, BurgerJet al. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer119(21), 3805–3811 (2013).
   PubMed Web of Science ®Google Scholar
• Eichhorst B , FinkAM, BuschRet al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood124(21), 19 (2014) ( Abstract 19).
   Web of Science ®Google Scholar
• IMBRUVICA® (ibrutinib capsules) . Full Prescribing Information. Janssen Biotech, Inc., Horsham, PA, USA (2016).
   Google Scholar
• Dohner H , StilgenbauerS, BennerAet al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med.343(26), 1910–1916 (2000).
   PubMed Web of Science ®Google Scholar
• VENCLEXTA™ (venetoclax tablets) . Full Prescribing Information. AbbVie Inc., North Chicago, IL, USA (2016).
   Google Scholar
• O’Brien SM , LamannaN, KippsTJet al. A Phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood126(25), 2686–2694 (2015).
   PubMed Web of Science ®Google Scholar
• Furman RR , SharmanJP, CoutreSEet al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med.370(11), 997–1007 (2014).
   PubMed Web of Science ®Google Scholar
• Lannutti BJ , MeadowsSA, HermanSEet al. CAL-101, a p110delta-selective phosphatidylinositol-3-kinase (PI3K) inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood117(2), 591–594 (2011).
   PubMed Web of Science ®Google Scholar
• ZYDELIG® (idelalisib tablets) . Full Prescribing Information. Gilead Sciences, Inc., Foster City, CA, USA (2014).
   Google Scholar
• Vanhaesebroeck B , Guillermet-GuibertJ, GrauperaM, BilangesB. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol.11(5), 329–341 (2010).
   PubMed Web of Science ®Google Scholar
• Srinivasan L , SasakiY, CaladoDPet al. PI3 kinase signals BCR-dependent mature B cell survival. Cell139(3), 573–586 (2009).
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B , WelhamMJ, KotaniKet al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl Acad. Sci. USA94(9), 4330–4335 (1997).
   PubMed Web of Science ®Google Scholar
• Chantry D , VojtekA, KashishianAet al. P110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Biol. Chem.272(31), 19236–19241 (1997).
   PubMed Web of Science ®Google Scholar
• Khan M , SaifA, SandlerS, MirrakhimovAE. Idelalisib for the treatment of chronic lymphocytic leukemia. ISRN Oncol.2014, 931858 (2014).
   PubMedGoogle Scholar
• Jou ST , CarpinoN, TakahashiYet al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol. Cell. Biol.22(24), 8580–8591 (2002).
   PubMed Web of Science ®Google Scholar
• Okkenhaug K , BilancioA, FarjotGet al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science297(5583), 1031–1034 (2002).
   PubMed Web of Science ®Google Scholar
• Clayton E , BardiG, BellSEet al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med.196(6), 753–763 (2002).
   PubMed Web of Science ®Google Scholar
• Herman SE , GordonAL, WagnerAJet al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood116(12), 2078–2088 (2010).
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J , MeadowsSA, SivinaMet al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood118(13), 3603–3612 (2011).
   PubMed Web of Science ®Google Scholar
• Fiorcari S , BrownWS, McIntyreBWet al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS ONE8(12), e83830 (2013).
   PubMed Web of Science ®Google Scholar
• Webb H , ChenH, YuAet al. Clinical pharmacokinetics of CAL-101, a p110δ isoform-selective PI3K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies [Poster I-754]. Presented at: American Society of Hematology Annual Meeting. Orlando, FL, USA, 4–7 December 2010.
   Google Scholar
• Jin F , RobesonM, ZhouH, KwanE, RamanathanS. Pharmacokinetics, metabolism and excretion of idelalisib. Presented at: 55th American Society of Hematology Annual Meeting and Exposition. New Orleans, LA, USA, 7–10 December 2013.
   Google Scholar
• Jin F , RobesonM, ZhouH, HisoireG, RamanathanS. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment. Cancer Chemother. Pharmacol.76(6), 1133–1141 (2015).
   PubMed Web of Science ®Google Scholar
• Jin F , RobesonM, ZhouH, HisoireG, RamanathanS. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. J. Clin. Pharmacol.55(8), 944–952 (2015).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . Idelalisib. Summary of Product Characteristics. www.medicines.org.uk/emc/medicine/29202.
   Google Scholar
• Brown JR , ByrdJC, CoutreSEet al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood123(22), 3390–3397 (2014).
   PubMed Web of Science ®Google Scholar
• Cheson BD , PfistnerB, JuweidMEet al. Revised response criteria for malignant lymphoma. J. Clin. Oncol.25(5), 579–586 (2007).
   PubMed Web of Science ®Google Scholar
• Barrientos JC , CoutreSE, de VosSet al. Long-term follow-up of a Phase 1 trial of idelalisib (ZYDELIG®) in combination with bendamustine (B), bendamustine/rituximab (BR), fludarabine (F), chlorambucil (Chl), or chlorambucil/rituximab (ChlR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood124(21), 3343 (2014).
   Web of Science ®Google Scholar
• Furman RR , de VosS, LeonardJPet al. A Phase 1 study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia. Blood122(21), 4180 (2013).
   Google Scholar
• Zelenetz AD , LamannaN, KippsTJet al. A Phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood124(121), 1986 (2014).
   Google Scholar
• Zelenetz AD , RobakT, CoiffierBet al. Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: results of a Phase 3 randomized double-blind placebo-controlled study. Blood126(23), Abstract LBA-5 (2015).
   PubMed Web of Science ®Google Scholar
• Zelenetz A , LamannaN, KippsTet al. A Phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Presented at: XVI International Workshop on Chronic Lymphocytic Leukemia. Sydney, Australia, 6–9 September 2015.
   Google Scholar
• Sharman JP , CoutreSE, FurmanRRet al. Second interim analysis of a Phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. Blood124(21), 330 (2014).
   Web of Science ®Google Scholar
• Lampson BL , MatosT, KimHTet al. Idelalisib given front-line for the treatment of chronic lymphocytic leukemia results in frequent and severe immune-mediated toxicities. Blood126(23), 497 (2015).
   Web of Science ®Google Scholar
• Coutre SE , BarrientosJC, BrownJRet al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk. Lymphoma56(10), 2779–2786 (2015).
   PubMed Web of Science ®Google Scholar
• Hodgson K , FerrerG, MontserratE, MorenoC. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica96(5), 752–761 (2011).
   PubMed Web of Science ®Google Scholar
• Jones JA , HillmenP, CoutreSet al. Pattern of use of anticoagulation and/or antiplatelet agents in patients with chronic lymphocytic leukemia (CLL) treated with single-agent ibrutinib therapy [abstract]. Blood124(21), 1990 (2014).
   Web of Science ®Google Scholar
• Barrientos J , GhiaP, PagelJet al. Outcomes of anticoagulant or antiplatelet use in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma in idelalisib trials. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 29 May–2 June 2015.
   Google Scholar
• FDA alerts healthcare professionals about clinical trials with Zydelig (idelalisib) in combination with other cancer medicines. www.fda.gov/Drugs/DrugSafety/ucm490618.htm.
   Google Scholar
• Direct Healthcare Professional Communication: restrictions on the use of Zydelig® (idelalisib) for the treatment of chronic lymphocytic leukaemia (CLL) and relapsed follicular lymphoma (FL) following new clinical trial results. www.hpra.ie/docs/default-source/default-document-library/important-safety-information---zydelig-(idelalisib).pdf?sfvrsn=0.
   Google Scholar
• Jain P , KeatingM, WierdaWet al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood125(13), 2062–2067 (2015).
   PubMed Web of Science ®Google Scholar
• Maddocks KJ , RuppertAS, LozanskiGet al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol.1(1), 80–87 (2015).
   PubMed Web of Science ®Google Scholar
• Mato A , NabhanC, BarrPMet al. Favorable outcomes in CLL pts with alternate kinase inhibitors following ibrutinib or idelalisib discontinuation: results from a large multi-center study. Blood126(23), 719 (2015).
   Web of Science ®Google Scholar
• Barrientos J , KaurM, MarkAet al. Outcomes of patients with chronic lymphocytic leukemia (CLL) after idelalisib therapy discontinuation. A4155. Blood126(23), 4155 (2015).
   Web of Science ®Google Scholar
• Byrd JC , FurmanRR, CoutreSEet al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood125(16), 2497–2506 (2015).
   PubMed Web of Science ®Google Scholar
• Dreger P , ScheteligJ, AndersenNet al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 124(26), 3841–3849 (2014).
   PubMed Web of Science ®Google Scholar
• O’Brien S , FaiaK, WhiteKet al. Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-delta, gamma inhibitor, in patients with treatment-naïve CLL. Haematologica100(Suppl. 1), 154–155 (2015).
   Google Scholar
• O’Brien S , PatelM, KahlBSet al. Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia. Blood124, 21 (2014).
   Web of Science ®Google Scholar
• Porcu P , FlinnI, KahlBSet al. Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, in patients previously treated with ibrutinib. Blood124, 21 (2014).
   Web of Science ®Google Scholar
• O’Connor OA , FlinnIW, PatelMRet al. TGR-1202, a novel once daily PI3K-delta inhibitor, demonstrates clinical activity with a favorable safety profile in patients with CLL and B-cell lymphoma. Blood126(23), 4154 (2015).
   Web of Science ®Google Scholar
• Roberts AW , DavidsMS, PagelJMet al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med.374(4), 311–322 (2016).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S , EichhorstBF, ScheteligJet al. Venetoclax (ABT-199/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion: results of the pivotal international Phase 2 study. Blood126(23), Abstract LBA-6 (2015).
   PubMed Web of Science ®Google Scholar
• Cheah CY , NastoupilLJ, NeelapuSS, ForbesSG, OkiY, FowlerNH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood125(21), 3357–3359 (2015).
   PubMed Web of Science ®Google Scholar
• Smith SM , PitcherB, JungS-Het al. Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: alliance A051201 and A051202. Blood124(21), 3091 (2014).
   Web of Science ®Google Scholar